RocketVax is a Swiss biotech company utilizing proprietary reverse genetic engineering and molecular biology techniques to develop live-attenuated vaccines that provide long-lasting immunity against SARS-CoV-2. Their nasal vaccine formulation offers broad immune responses, stability at regular temperatures, and effective protection against current and future virus variants, addressing the limitations of existing vaccines.
Funding
$2 raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current COVID-19 vaccines may not offer long-lasting immunity, can be vulnerable to virus mutations, and often require complex cold-chain logistics, limiting their effectiveness against new infections and hindering global distribution. Existing vaccines also primarily induce systemic immunity, potentially missing the opportunity to prevent infection at the mucosal level.
Solution
RocketVax is developing a live-attenuated SARS-CoV-2 nasal vaccine designed to provide broad and durable immunity against current and future variants. By mimicking the natural infection route, the vaccine induces both mucosal and systemic immune responses, potentially preventing reinfection and limiting virus spread. The vaccine is engineered for stability at regular temperatures, simplifying distribution and storage, and is designed to expose the immune system to the entire repertoire of SARS-CoV-2 antigens, triggering comprehensive antibody and T-cell responses. RocketVax leverages proprietary reverse genetic engineering and molecular biology techniques to create next-generation vaccines that aim to outperform existing options.
Target Audience
The primary target audience includes individuals seeking long-lasting protection against COVID-19 and healthcare providers aiming to improve vaccine accessibility and effectiveness.
Features
- Live-attenuated vaccine designed to generate broad immune responses against all virus proteins.
- Intranasal administration mimicking the natural infection route to induce mucosal and systemic immunity.
- Designed to be effective against circulating and future SARS-CoV-2 variants.
- Stable formulation that does not require ultracold storage.
- Designed for cost-efficient manufacturing.
- Readily adaptable vaccine design based on the latest scientific data.